The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population-Reference-Cited by-同舟云学术

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population

Published:2010-03-24 Issue:7 Volume:85 Page:525-528
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Racil Zdenek,Razga Filip,Buresova Lucie,Jurcek Tomas,Dvorakova Dana,Zackova Daniela,Timilsina Shira,Cetkovsky Petr,Mayer Jiri

Publisher

Wiley

Subject

Hematology

Reference11 articles.

1. Active transport of imatinib into and out of cells: Implications for drug resistance;Thomas;Blood,2004

2. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib;White;Blood,2006

3. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: Higher doses of imatinib may overcome the negative impact of low OCT-1 activity;White;Blood,2007

4. hOCT 1 and resistance to imatinib;Crossman;Blood,2005

5. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia;Wang;Clin Pharmacol Ther,2008

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia;Cancer Chemotherapy and Pharmacology;2017-03-12

2. Gene expression patterns as predictive biomarkers in hematology-oncology: principal hurdles on the road to the clinic;Haematologica;2016-12-31

3. Overexpression of ABCB1 as prediction marker for CML: How close we are to translation into clinics?;Leukemia;2016-10-21

4. Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry;Analytical Letters;2014-03-28

5. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia;Leukemia & Lymphoma;2014-03-19